0001104659-24-045283.txt : 20240409 0001104659-24-045283.hdr.sgml : 20240409 20240409172612 ACCESSION NUMBER: 0001104659-24-045283 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240409 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240409 DATE AS OF CHANGE: 20240409 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 24833643 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 8-K 1 tm2411445d1_8k.htm FORM 8-K
false 0001585608 0001585608 2024-04-09 2024-04-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 9, 2024 

 

 

 

JAGUAR HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-36714 46-2956775
(State or other jurisdiction of
incorporation)		 (Commission File Number) (IRS Employer Identification No.)

 

200 Pine Street, Suite 400

San Francisco, California

 94104
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (415) 371-8300 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, Par Value $0.0001 Per Share JAGX The Nasdaq Capital Market

 

 

 

 

 

 

Item 5.07   Submission of Matters to a Vote of Security Holders.

 

On April 9, 2024, Jaguar Health, Inc. (the “Company”) held a special meeting of stockholders of the Company (the “Special Meeting”). Four proposals were submitted to and approved by the Company’s stockholders, each of which is described in the Company’s definitive proxy statement for the Special Meeting (the “Proxy Statement”), filed with the Securities and Exchange Commission on March 15, 2024. At the Special Meeting, a total of 72,298,335 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), out of a total of 206,757,242 shares of Common Stock issued and outstanding and entitled to vote, and a total of 179.3822 shares of the Company’s Series J Preferred Stock, par value $0.0001 per share (the “Preferred Stock”), representing all of the issued and outstanding shares of Preferred Stock entitled to vote at the Special Meeting, each as of March 1, 2024, the record date for the Special Meeting, were represented in person or by proxy at the Special Meeting. As described in the Proxy Statement, each share of Preferred Stock entitled the holder of record thereof to 424,304 votes on Proposals 1, 3, and 4 at the Special Meeting; provided, that, such shares of Series J Preferred Stock were only entitled to vote on Proposals 1, 3 and 4 and any holder of Series J Preferred Stock is not entitled to vote, on an as-converted basis and in the aggregate with respect to any shares of Common Stock and preferred stock of the Company beneficially owned by such holder and any Affiliates or Attribution Parties (as such terms are defined in the Certificate of Designation of Series J Preferred Stock) of such holder, more than 9.99% of the Company’s outstanding shares of Common Stock as of the applicable record date.

 

The final results for the votes regarding each proposal are set forth below.

 

  1.Proposal to approve an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s issued and outstanding voting common stock, par value $0.0001 per share, at a ratio of not less than 1-for-2 and not greater than 1-for-150, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Company’s board of directors and publicly announced by the Company on or before January 22, 2025 without further approval or authorization of the Company’s stockholders, was approved by the stockholders by the following vote:

 

For   Against     Abstained   Broker Non-
Votes		  
73,520,240   19,147,290     285,853   0  

  

  2.Proposal to approve, pursuant to Nasdaq Marketplace Rule 5635(d), the issuance of Company’s common stock upon exchange of shares of Series J Preferred Stock issued to certain accredited investors, was approved by the stockholders by the following vote:

 

For   Against     Abstained   Broker Non-
Votes		  
34,430,429   11,120,770     1,024,155   25,722,981  

  

  3.Proposal to approve, pursuant to Nasdaq Marketplace Rule 5635(d), the issuance of 18,837,500 shares of Common Stock to certain accredited investors pursuant to the exchange agreements, dated February 27, 2024, between us and such investors (the “PIPE Warrant Exchange Agreements”), in exchange for certain warrants to acquire shares of Common Stock previously issued to such investors, was approved by the stockholders by the following vote:

 

For   Against     Abstained   Broker Non-
Votes		  
55,863,424   10,656,130     710,848   25,722,981  

  

  4.Proposal to approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposals 1, 2, and 3 was approved by the stockholders by the following vote :

 

For   Against     Abstained   Broker Non-
Votes		  
75,565,231   15,556,724     1,831,428   0  

  

2 

 

 

Item 7.01. Regulation FD Disclosure.

 

On April 9, 2024, the Company issued a press release announcing the results of the Special Meeting, a copy of which is furnished as Exhibit 99.1.

 

The information in Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

 

Item 8.01 Other Events.

 

As previously reported, on May 10, 2023, the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) issued the Company a notification citing the Company's failure to comply with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was initially provided 180 calendar days, or until November 6, 2023, and was subsequently granted an additional 180 calendar day period, or until May 6, 2024, to regain compliance with the Minimum Bid Price Requirement. However, on February 15, 2024, the Company received a delisting determination letter from the Staff in accordance with Nasdaq Listing Rule 5810(c)(3)(A)(iii) due to the Company’s securities having a closing bid price of $0.10 or less for ten consecutive trading days. Accordingly, on February 29, 2024, the Company requested a hearing before the Nasdaq Hearings Panel (the “Panel”) which automatically stayed the delisting of the Company’s common stock from Nasdaq pending a decision from the Panel. Pursuant to an expedited review process, whereby the Company submitted responses to a written questionnaire regarding its plan to regain compliance with the Minimum Bid Price Requirement, the Panel provided notice on April 5, 2024 granting the Company’s request to extend the period for the Company to regain compliance with the Minimum Bid Price Requirement until August 13, 2024.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)  Exhibits

 

Exhibit No.   Description
99.1   Press Release Announcing Results of the 2024 Special Meeting of Stockholders of the Company, dated April 9, 2024.
104   Cover Page Interactive Data File (embedded within the inline XBRL document)

 

3 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  JAGUAR HEALTH, INC.
       
  By:   /s/ Lisa A. Conte
      Name: Lisa A. Conte
      Title: Chief Executive Officer & President
         
Date: April 9, 2024        

 

4 

 

 

 

 

 EX-99.1 2 tm2411445d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders

 

Company not implementing a reverse split at this time

 

Top line results forthcoming for company’s phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea

 

San Francisco, CA (April 9, 2024): Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) today announced the voting results of the Company’s Special Meeting of Stockholders held on April 9, 2024 (the “Special Meeting”).

 

Four proposals were submitted to and approved by the stockholders of the Company at the Special Meeting. The proposals are described in detail in the Company’s definitive proxy statement on Schedule 14A relating to the Special Meeting and supplemental information filed with the Securities and Exchange Commission on March 15, 2024. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at http://www.sec.gov. The proxy statement is also available on the Company’s corporate website.

 

“As we announced last week, the Company received formal notice that the Listing Qualifications Staff of The Nasdaq Stock Market LLC has granted Jaguar an additional grace period, through August 13, 2024, to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. Although we do not intend to effect a reverse split of the Company’s issued and outstanding voting common stock at the present time, seeking the discretion to implement actions, if necessary to maintain Jaguar’s Nasdaq listing, is an important responsibility of the Board, and we are grateful to our shareholders for voting to approve the related proposal,” said Lisa Conte, Jaguar's president, and CEO.

 

Jaguar’s paramount near-term clinical activity is the Company’s Phase 3 pivotal OnTarget trial of crofelemer for the follow-on indication of the preventative treatment of cancer therapy-related diarrhea. Top line results from this pivotal study are forthcoming.

 

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals’ crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

 

 

 

 

 

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

 

Visit Jaguar on LinkedIn: https://www.linkedin.com/company/jaguar-health/

Visit Jaguar on X: https://twitter.com/Jaguar_Health

Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/

 

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar's expectation that top line results from the OnTarget study are forthcoming. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

 

Source: Jaguar Health, Inc.

 

Contact:

hello@jaguar.health

 

Jaguar-JAGX

 

 

 EX-101.SCH 3 jagx-20240409.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 jagx-20240409_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 jagx-20240409_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2411445d1_ex99-1img001.jpg GRAPHIC begin 644 tm2411445d1_ex99-1img001.jpg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tm2411445d1_ex99-1img002.jpg GRAPHIC begin 644 tm2411445d1_ex99-1img002.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
Apr. 09, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 09, 2024
Entity File Number 001-36714
Entity Registrant Name JAGUAR HEALTH, INC.
Entity Central Index Key 0001585608
Entity Tax Identification Number 46-2956775
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 200 Pine Street
Entity Address, Address Line Two Suite 400
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94104
City Area Code 415
Local Phone Number 371-8300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.0001 Per Share
Trading Symbol JAGX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $6+B5@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !%BXE8^^)/,.\ K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R$E'8";UI66G#08K;.QF;+4UC1UC:R1]^SE9FS*V!QCX8NGW MIT_@5@>A^X@OL0\8R6*Z&UWGD]!AS8Y$00 D?42G4ID3/C?W?72*\C4>("A] M4@>$FO,&')(RBA1,P"(L1"9;HX6.J*B/%[S1"SY\QFZ&&0W8H4-/":JR B:G MB>$\=BW< !.,,+KT74"S$.?JG]BY ^R2')-=4L,PE,-JSN4=*GA_?GJ=URVL M3Z2\QOPJ64'G@&MVG?RVVFQWCTS6O+XO>#X/N[H2=2-X\S&Y_O"[";O>V+W] MQ\970=G"KW\AOP!02P,$% @ 18N)6)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" !%BXE8[IW8?EX$ ?$0 & 'AL+W=OI[1GB.!?W9I2]7K- M$KD=.9[SMN.1KS?&[FB-AQE=LY"9K]E%?7?M<& M%&=\XVRK#[:)O96EE$]V,(M'CFN)6,(B8R4H_#VS"4L2JP0<_^Y%G?*:-O!P M^TW]MKAYN)DEU6PBD^\\-IN1,W!(S%8T3\RCW-ZQ_0T5@)%,=/%+MKMS.QV' M1+DV,MT' T'*Q>Z?ONP3<1C@'PGP]P%^P;V[4$%Y0PT=#Y7<$F7/!C6[4=QJ M$0UP7-A9"8V"HQSBS'@BGYD:M@Q(V1VM:!]VO0OSCX0%F;H@[N49\5V_\]_P M%A"4&'Z)X1=Z;0R#_!TLM5$P4?_4$>T4.O4*MGJO=$8C-G*@/#53S\P9__R3 MUW-_0_C:)5\;4Q_?R"B'6C1D\9JQ.C@\?'#^"8'HE! =5"4 @KB@N$WHNHX" MCU_11#.$HUMR=$]+QIPI+F,R%3&!XJO-"ZY4E%%11TV%U"O9>JCB5!AN7LDM M3QAYR--E?7'C&J[KG;=[?0_CZ9<\_5-X'MF:V]*&I#W0M#93N,[OP<>OP2.Y MFP;WB[LS,GN87"!T@Y)N< K=!"93T83,1,Q>R"?V6L>'*[F0M.Z@VW,'"-9E MB75Y"M:"OI!9#&Q\Q2-:F/CQ*<45.[US_[+;Z_>[")[G5J;IG@(X$Y%4F50% MVQD)#3P$1"HRD3DD%/(JX]JI;E"_F6*0!\[NG0(9Q#'XH3Y[VR#W+B#AS+A$3=UYP ]V97!'/_V7Y M*PE9E$.]U38=#4JV/J$K"(V,GL!4D>E+M*%BS8YVE0U"#T%X$_R! M,556[Y]D]=.4J;7-TD=0,!MK(1D5]9.+"QXMN-;!ZZ[]=/"9VBMJDK 5"+D7 M?=!5N[?QW<#(K'@#7DH#[]/%YH91>!CL"7!\):5Y&]B7ZO*;R/@'4$L#!!0 M ( $6+B5B?H!OPL0( .(, - >&PO9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC M.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[H MEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\ M&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG> MV)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH> MN77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K M SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P M0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC M=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX M3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U" ML)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0 MF,7XC&894IT,/O'^8* \^>Q\ETWLJ M.?]74_P$4$L#!!0 ( $6+B5B7BKL

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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://jaguaranimalhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports jagx-20240409.xsd jagx-20240409_lab.xml jagx-20240409_pre.xml tm2411445d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2411445d1_8k.htm": { "nsprefix": "jagx", "nsuri": "http://jaguaranimalhealth.com/20240409", "dts": { "schema": { "local": [ "jagx-20240409.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "jagx-20240409_lab.xml" ] }, "presentationLink": { "local": [ "jagx-20240409_pre.xml" ] }, "inline": { "local": [ "tm2411445d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://jaguaranimalhealth.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2411445d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2411445d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://jaguaranimalhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001104659-24-045283-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-045283-xbrl.zip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end XML 19 tm2411445d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001585608 2024-04-09 2024-04-09 iso4217:USD shares iso4217:USD shares false 0001585608 8-K 2024-04-09 JAGUAR HEALTH, INC. DE 001-36714 46-2956775 200 Pine Street Suite 400 San Francisco CA 94104 415 371-8300 false false false false false Common Stock, Par Value $0.0001 Per Share JAGX NASDAQ